210 related articles for article (PubMed ID: 37382903)
21. Dietary folate, but not choline, modifies neural tube defect risk in Shmt1 knockout mice.
Beaudin AE; Abarinov EV; Malysheva O; Perry CA; Caudill M; Stover PJ
Am J Clin Nutr; 2012 Jan; 95(1):109-14. PubMed ID: 22134951
[TBL] [Abstract][Full Text] [Related]
22. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S
PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371
[TBL] [Abstract][Full Text] [Related]
23. Pre-conception Folic Acid and Multivitamin Supplementation for the Primary and Secondary Prevention of Neural Tube Defects and Other Folic Acid-Sensitive Congenital Anomalies.
Wilson RD; ; Wilson RD; Audibert F; Brock JA; Carroll J; Cartier L; Gagnon A; Johnson JA; Langlois S; Murphy-Kaulbeck L; Okun N; Pastuck M; ; Deb-Rinker P; Dodds L; Leon JA; Lowel HL; Luo W; MacFarlane A; McMillan R; Moore A; Mundle W; O'Connor D; Ray J; Van den Hof M
J Obstet Gynaecol Can; 2015 Jun; 37(6):534-52. PubMed ID: 26334606
[TBL] [Abstract][Full Text] [Related]
24. Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment.
Bade AN; McMillan JM; Liu Y; Edagwa BJ; Gendelman HE
Mol Neurobiol; 2021 Nov; 58(11):5703-5721. PubMed ID: 34390469
[TBL] [Abstract][Full Text] [Related]
25. Effects and safety of periconceptional oral folate supplementation for preventing birth defects.
De-Regil LM; Peña-Rosas JP; Fernández-Gaxiola AC; Rayco-Solon P
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007950. PubMed ID: 26662928
[TBL] [Abstract][Full Text] [Related]
26. Guideline No. 427: Folic Acid and Multivitamin Supplementation for Prevention of Folic Acid-Sensitive Congenital Anomalies.
Wilson RD; O'Connor DL
J Obstet Gynaecol Can; 2022 Jun; 44(6):707-719.e1. PubMed ID: 35691683
[TBL] [Abstract][Full Text] [Related]
27. Insights into prevention of human neural tube defects by folic acid arising from consideration of mouse mutants.
Harris MJ
Birth Defects Res A Clin Mol Teratol; 2009 Apr; 85(4):331-9. PubMed ID: 19117321
[TBL] [Abstract][Full Text] [Related]
28. Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?
Chouchana L; Beeker N; Treluyer JM
J Acquir Immune Defic Syndr; 2019 Aug; 81(4):481-486. PubMed ID: 31021990
[TBL] [Abstract][Full Text] [Related]
29. Assessing the risk of dolutegravir for women of childbearing potential.
Schomaker M; Davies MA; Cornell M; Ford N
Lancet Glob Health; 2018 Sep; 6(9):e958-e959. PubMed ID: 30049617
[No Abstract] [Full Text] [Related]
30. Fumonisin B₁ induced neural tube defects were not increased in LM/Bc mice fed folate-deficient diet.
Voss KA; Riley RT; Gelineau-van Waes J
Mol Nutr Food Res; 2014 Jun; 58(6):1190-8. PubMed ID: 24585430
[TBL] [Abstract][Full Text] [Related]
31. High levels of iron supplementation prevents neural tube defects in the Fpn1
Stokes BA; Sabatino JA; Zohn IE
Birth Defects Res; 2017 Jan; 109(2):81-91. PubMed ID: 28008752
[TBL] [Abstract][Full Text] [Related]
32. Gene-nutrient interactions that impact magnesium homeostasis increase risk for neural tube defects in mice exposed to dolutegravir.
Gelineau-van Waes J; van Waes MA; Hallgren J; Hulen J; Bredehoeft M; Ashley-Koch AE; Krupp D; Gregory SG; Stessman HA
Front Cell Dev Biol; 2023; 11():1175917. PubMed ID: 37377737
[TBL] [Abstract][Full Text] [Related]
33. Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008-20: a national cohort study.
Kourtis AP; Zhu W; Lampe MA; Huang YA; Hoover KW
Lancet HIV; 2023 Sep; 10(9):e588-e596. PubMed ID: 37506721
[TBL] [Abstract][Full Text] [Related]
34. Switch to dolutegravir is well tolerated in Thais with HIV infection.
Goh OQ; Colby DJ; Pinyakorn S; Sacdalan C; Kroon E; Chan P; Chomchey N; Kanaprach R; Prueksakaew P; Suttichom D; Trichavaroj R; Spudich S; Robb ML; Phanuphak P; Phanuphak N; Ananworanich J;
J Int AIDS Soc; 2019 Jul; 22(7):e25324. PubMed ID: 31294931
[TBL] [Abstract][Full Text] [Related]
35. Shmt1 and de novo thymidylate biosynthesis underlie folate-responsive neural tube defects in mice.
Beaudin AE; Abarinov EV; Noden DM; Perry CA; Chu S; Stabler SP; Allen RH; Stover PJ
Am J Clin Nutr; 2011 Apr; 93(4):789-98. PubMed ID: 21346092
[TBL] [Abstract][Full Text] [Related]
36. p53 Disruption Increases Uracil Accumulation in DNA of Murine Embryonic Fibroblasts and Leads to Folic Acid-Nonresponsive Neural Tube Defects in Mice.
Lachenauer ER; Stabler SP; Field MS; Stover PJ
J Nutr; 2020 Jul; 150(7):1705-1712. PubMed ID: 32271909
[TBL] [Abstract][Full Text] [Related]
37. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
[TBL] [Abstract][Full Text] [Related]
38. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?
Vitoria M; Hill A; Ford N; Doherty M; Clayden P; Venter F; Ripin D; Flexner C; Domanico PL
AIDS; 2018 Jul; 32(12):1551-1561. PubMed ID: 29746295
[TBL] [Abstract][Full Text] [Related]
39. Risk of birth defects and perinatal outcomes in HIV-infected women exposed to integrase strand inhibitors during pregnancy.
Sibiude J; Le Chenadec J; Mandelbrot L; Dollfus C; Matheron S; Lelong N; Avettand-Fenoel V; Brossard M; Frange P; Reliquet V; Warszawski J; Tubiana R;
AIDS; 2021 Feb; 35(2):219-226. PubMed ID: 33048878
[TBL] [Abstract][Full Text] [Related]
40. Dolutegravir Impairs Stem Cell-Based 3D Morphogenesis Models in a Manner Dependent on Dose and Timing of Exposure: An Implication for Its Developmental Toxicity.
Kirkwood-Johnson L; Katayama N; Marikawa Y
Toxicol Sci; 2021 Nov; 184(2):191-203. PubMed ID: 34515794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
